SYDNEY, AUSTRALIA--(Marketwired - April 19, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") today released its Appendix 4C - Quarterly Report for the three month period ending 31 March 2013. The Company had A$25.18 million in cash and term deposits as of the end of the quarter. The majority of funds spent during the quarter are related to development activities of Prima's lead product CVac™.
Prima's management will hold a conference call to present its quarterly results as well as explain the details of the Share Purchase Plan offer currently open to Australian and New Zealand shareholders of record as of 28 March 2013.
The call is scheduled for Wednesday, the 24th of April 2013 at 9:00am (Sydney local time). This corresponds to Tuesday, the 23rd of April at 7:00pm U.S. Eastern daylight time. The conference call dial-in numbers are as follows:
Australia Toll Free
1 800 131 617
Australia Alternate Toll Free
1 800 838 758
1 855 624 0077
0800 183 0918
The call will also be audio webcast with additional supplemental slides available via http://services.choruscall.com/links/primabiomed130422.html. Before launching the webcast, it is recommended to click on the link and then on "test your systems configuration."
A replay and a transcript of the teleconference will be available through Prima's website following the live event.
About Prima BioMed
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.